FDA Clears Emerging AI-Powered Software for Brain MRI
Leveraging AI technology, the AiMIFY software reportedly facilitates double the contrast enhancement in comparison to gadolinium-based contrast agents (GBCAs) for brain MRI.
Offering enhanced imaging capability for detection of lesions on brain magnetic resonance imaging (MRI), the artificial intelligence (AI)-enabled software AiMIFY has been granted clearance from the Food and Drug Administration (FDA) for a class II software as a medical device (SaMD).
Co-developed by Bracco Diagnostics and Subtle Medical, AiMIFY enhances contrast on brain MRI to a level that is double the contrast generated with labeled dosing of gadolinium-based contrast agents (GBCAs). The increased imaging clarity bolsters the detection of small lesions on brain MRI, according to the companies.
The recently FDA-cleared AI software AiMIFY reportedly enhances contrast on brain MRI to a level that is double the contrast generated with labeled dosing of gadolinium-based contrast agents (GBCAs). (Image courtesy of Adobe Stock.)
The companies emphasized research validation of aiMIFY use with a variety of vendor scanners and MRI sequences as well as datasets including diverse patient demographics and pathologies.
"By integrating Bracco's expertise in contrast imaging with Subtle Medical's cutting-edge deep-learning technology, we are poised to redefine diagnostic precision and efficiency, setting new standards in the field for the ultimate benefit of the patients,” noted Fulvio Renoldi Bracco, the vice chairman and CEO of Bracco Imaging.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
